Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL011 versus MabThera in severe active rheumatoid arthritis on methotrexate
2011-005021-48Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of IBI301 in rheumatoid arthritis (RA) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Therapeutic equivalence of TL011 to rituximab. Started Feb 2012; status: terminated.
02
Drugs
IBI301
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-005021-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005021-48.